232 related articles for article (PubMed ID: 17328059)
1. Suppression of inflammation and structural damage in experimental arthritis through molecular targeted therapy with PPI-2458.
Hannig G; Bernier SG; Hoyt JG; Doyle B; Clark E; Karp RM; Lorusso J; Westlin WF
Arthritis Rheum; 2007 Mar; 56(3):850-60. PubMed ID: 17328059
[TBL] [Abstract][Full Text] [Related]
2. An inhibitor of methionine aminopeptidase type-2, PPI-2458, ameliorates the pathophysiological disease processes of rheumatoid arthritis.
Lazarus DD; Doyle EG; Bernier SG; Rogers AB; Labenski MT; Wakefield JD; Karp RM; Clark EJ; Lorusso J; Hoyt JG; Thompson CD; Hannig G; Westlin WF
Inflamm Res; 2008 Jan; 57(1):18-27. PubMed ID: 18209961
[TBL] [Abstract][Full Text] [Related]
3. IKKbeta inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis.
Schopf L; Savinainen A; Anderson K; Kujawa J; DuPont M; Silva M; Siebert E; Chandra S; Morgan J; Gangurde P; Wen D; Lane J; Xu Y; Hepperle M; Harriman G; Ocain T; Jaffee B
Arthritis Rheum; 2006 Oct; 54(10):3163-73. PubMed ID: 17009244
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of melanoma tumor growth by a pharmacological inhibitor of MetAP-2, PPI-2458.
Hannig G; Lazarus DD; Bernier SG; Karp RM; Lorusso J; Qiu D; Labenski MT; Wakefield JD; Thompson CD; Westlin WF
Int J Oncol; 2006 Apr; 28(4):955-63. PubMed ID: 16525646
[TBL] [Abstract][Full Text] [Related]
5. Metabolites of PPI-2458, a selective, irreversible inhibitor of methionine aminopeptidase-2: structure determination and in vivo activity.
Arico-Muendel CC; Belanger B; Benjamin D; Blanchette HS; Caiazzo TM; Centrella PA; DeLorey J; Doyle EG; Gradhand U; Griffin ST; Hill S; Labenski MT; Morgan BA; O'Donovan G; Prasad K; Skinner S; Taghizadeh N; Thompson CD; Wakefield J; Westlin W; White KF
Drug Metab Dispos; 2013 Apr; 41(4):814-26. PubMed ID: 23355637
[TBL] [Abstract][Full Text] [Related]
6. A novel methionine aminopeptidase-2 inhibitor, PPI-2458, inhibits non-Hodgkin's lymphoma cell proliferation in vitro and in vivo.
Cooper AC; Karp RM; Clark EJ; Taghizadeh NR; Hoyt JG; Labenski MT; Murray MJ; Hannig G; Westlin WF; Thompson CD
Clin Cancer Res; 2006 Apr; 12(8):2583-90. PubMed ID: 16638869
[TBL] [Abstract][Full Text] [Related]
7. A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis.
Bernier SG; Lazarus DD; Clark E; Doyle B; Labenski MT; Thompson CD; Westlin WF; Hannig G
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10768-73. PubMed ID: 15249666
[TBL] [Abstract][Full Text] [Related]
8. META060 inhibits osteoclastogenesis and matrix metalloproteinases in vitro and reduces bone and cartilage degradation in a mouse model of rheumatoid arthritis.
Konda VR; Desai A; Darland G; Bland JS; Tripp ML
Arthritis Rheum; 2010 Jun; 62(6):1683-92. PubMed ID: 20201075
[TBL] [Abstract][Full Text] [Related]
9. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction.
Zwerina J; Hayer S; Redlich K; Bobacz K; Kollias G; Smolen JS; Schett G
Arthritis Rheum; 2006 Feb; 54(2):463-72. PubMed ID: 16447221
[TBL] [Abstract][Full Text] [Related]
10. S-Adenosyl-L-homocysteine hydrolase inhibitor mediates immunosuppressive effects in vivo: suppression of delayed type hypersensitivity ear swelling and peptidoglycan polysaccharide-induced arthritis.
Saso Y; Conner EM; Teegarden BR; Yuan CS
J Pharmacol Exp Ther; 2001 Jan; 296(1):106-12. PubMed ID: 11123369
[TBL] [Abstract][Full Text] [Related]
11. Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis.
Gillooly KM; Pattoli MA; Taylor TL; Chen L; Cheng L; Gregor KR; Whitney GS; Susulic V; Watterson SH; Kempson J; Pitts WJ; Booth-Lute H; Yang G; Davies P; Kukral DW; Strnad J; McIntyre KW; Darienzo CJ; Salter-Cid L; Yang Z; Wang-Iverson DB; Burke JR
J Pharmacol Exp Ther; 2009 Nov; 331(2):349-60. PubMed ID: 19652024
[TBL] [Abstract][Full Text] [Related]
12. Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis.
Cejka D; Hayer S; Niederreiter B; Sieghart W; Fuereder T; Zwerina J; Schett G
Arthritis Rheum; 2010 Aug; 62(8):2294-302. PubMed ID: 20506288
[TBL] [Abstract][Full Text] [Related]
13. Involution of collagen-induced arthritis with an angiogenesis inhibitor, PPI-2458.
Brahn E; Schoettler N; Lee S; Banquerigo ML
J Pharmacol Exp Ther; 2009 May; 329(2):615-24. PubMed ID: 19218530
[TBL] [Abstract][Full Text] [Related]
14. NE-58095: a diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis.
Francis MD; Hovancik K; Boyce RW
Int J Tissue React; 1989; 11(5):239-52. PubMed ID: 2517540
[TBL] [Abstract][Full Text] [Related]
15. A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti-tumor necrosis factor monoclonal antibody in murine collagen-induced arthritis.
Saito H; Kojima T; Takahashi M; Horne WC; Baron R; Amagasa T; Ohya K; Aoki K
Arthritis Rheum; 2007 Apr; 56(4):1164-74. PubMed ID: 17393436
[TBL] [Abstract][Full Text] [Related]
16. Novel phosphoinositide 3-kinase δ,γ inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis.
Boyle DL; Kim HR; Topolewski K; Bartok B; Firestein GS
J Pharmacol Exp Ther; 2014 Feb; 348(2):271-80. PubMed ID: 24244039
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effect of urocortin on collagen-induced arthritis by down-regulation of inflammatory and Th1 responses and induction of regulatory T cells.
Gonzalez-Rey E; Chorny A; Varela N; O'Valle F; Delgado M
Arthritis Rheum; 2007 Feb; 56(2):531-43. PubMed ID: 17265488
[TBL] [Abstract][Full Text] [Related]
18. Bone protective effect of simvastatin in experimental arthritis.
Funk JL; Chen J; Downey KJ; Clark RA
J Rheumatol; 2008 Jun; 35(6):1083-91. PubMed ID: 18464303
[TBL] [Abstract][Full Text] [Related]
19. Fcgamma receptors directly mediate cartilage, but not bone, destruction in murine antigen-induced arthritis: uncoupling of cartilage damage from bone erosion and joint inflammation.
van Lent PL; Grevers L; Lubberts E; de Vries TJ; Nabbe KC; Verbeek S; Oppers B; Sloetjes A; Blom AB; van den Berg WB
Arthritis Rheum; 2006 Dec; 54(12):3868-77. PubMed ID: 17133594
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
